Objectif Aenitis Technologies develops innovative solutions for separating, sorting and filtration of cells in suspension based on patented acoustophoresis technologies (pheresis based on acoustic radiation forces influence on polydisperced suspension). Aenitis’ first axis of development is an innovative blood fractionation medical device for the production of labile blood products (LBP). It will overtake limits of currently used centrifugation processes which have many adverse effects as platelet activation (mainly due to induced shear forces). Aenitis approach revolutionizes the sector as it permit in a secure and simple process to product LBP. It also avoids platelet activation as shear forces are very low in acoustophoresis process. This innovative Acoustic Blood Cells Sorter (ABC-S) project is highly recognized and awarded. It will solves major healthcare issues in LBP preparation by developing an innovative instrument capable of fractionating blood in continuous, without contact or pressure and with very low shear forces, to produce from whole blood high quality LBP. It will include the development of a platelet concentrate quality then unequalled in the world with a potentially conservation time significantly increased. This medical device will be associated with a disposable medical device to the source of recurring revenue. Blood medical devices world market is estimate to $14 Billion with an average growth annual rate of 5.5%. Yearly, 108 million blood donations are processed worldwide, including over 300 million in Europe and 460 million in North America. Our technology will have major impact for all blood banks’ LBP production; inducing a new gold standard driven by Europe. This proposal for the call H2020 SME Instrument Phase 1 “Supporting innovative SMEs in the healthcare biotechnology sector: Cell technologies in medical applications” will permit Aenitis to grow from a functional laboratory-scale prototype to preindustrial prototypes first steps. Champ scientifique medical and health scienceshealth sciencespublic healthnatural sciencesphysical sciencesacousticsmedical and health sciencesmedical biotechnologycells technologies Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur AENITIS TECHNOLOGIES Contribution nette de l'UE € 50 000,00 Adresse 56 RUE PAUL VAILLANT COUTURIER 77290 MITRY MORY France Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Ile-de-France Ile-de-France Seine-et-Marne Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
